AbbVie Inc (ABBV)vsApyx Medical Inc (APYX)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
APYX
Apyx Medical Inc
$3.46
-5.72%
HEALTHCARE · Cap: $144.73M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 115637% more annual revenue ($61.16B vs $52.84M). ABBV leads profitability with a 6.9% profit margin vs -21.2%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
APYX
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+44.7%
Fair Value
$7.09
Current Price
$3.46
$3.63 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 34.7% year-over-year
Growing faster than its price suggests
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 9.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : APYX
The strongest argument for APYX centers on Revenue Growth, PEG Ratio. Revenue growth of 34.7% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : APYX
The primary concerns for APYX are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while APYX is a hypergrowth play — different risk/reward profiles.
APYX carries more volatility with a beta of 1.54 — expect wider price swings.
APYX is growing revenue faster at 34.7% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 40/100). APYX offers better value entry with a 44.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Apyx Medical Inc
HEALTHCARE · MEDICAL DEVICES · USA
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?